

This statement was issued by Shire HGT on 09-Jan-2009.  
For more information on HGT-1111 and updated clinical trial information please go to:  
<http://MLDfoundation.org>

### **MLD Patient Association and KOL Update**

Since the acquisition of the investigational ERT for the treatment of MLD in 2008, Shire HGT has been actively working on the development of this program. Based upon discussions with our key opinion leaders at an advisory board in the third quarter of 2008, Shire HGT is currently refining our clinical development plan and we will share the details of this plan later this year.

As we previously communicated, Shire HGT was actively evaluating opportunities to increase the production capacity for this ERT. Unfortunately, the existing contract manufacturer will not be able to supply any additional drug, over what we estimate will be required for our clinical trial program. As a result, Shire HGT will not be able to offer access to HGT-1111, outside of clinical trials, in 2009 and 2010. However, over the next two years, Shire HGT will bring the manufacture of the compound in-house for future supply of HGT-1111 at a larger scale. Once the compound is being manufactured in-house and at larger scale production, Shire HGT will reevaluate our capacity and potential for a pre-approval access program.

Shire HGT is committed to bringing this much needed therapy to MLD patients as soon as possible and we are dedicated to informing all constituencies about our progress in a timely fashion. For any clarifying questions, please contact:

#### **Global Medical Affairs Contact:**

North America:  
Carol Cannon  
Medical Science Liaison Director  
[ccannon@shire.com](mailto:ccannon@shire.com)  
Office: +1 719 471 8173

ROW:  
Steve Moloney, MD  
Senior European Medical Director  
Tel: +44 (0) 1256 894508  
Fax: + 44 (0) 1256 894405  
Mobile: + 44 (0) 7770 814107  
Email: [smoloney@shire.com](mailto:smoloney@shire.com)

#### **Clinical Contact:**

Norman W. Barton, MD, PhD  
Principal Medical Director  
[nbarton-c@shire.com](mailto:nbarton-c@shire.com)